Image Place holder

Rohit K. Jain, MD, MPH


Specialty: Hematology/Oncology
Program: Genitourinary Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Prostate Cancer , Testicular Cancer , Bladder Cancer , Kidney (Renal Cell) Cancer

Dr. Rohit Jain is Assistant Member in the Moffitt Cancer Center Department of Genitourinary Oncology. Dr. Jain earned his MBBS at Topiwala National Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India. He completed an Internal Medicine Residency at Johns Hopkins University/Sinai Hospital of Baltimore. Dr. Jain recently completed a Hematology-Oncology Fellowship at Roswell Park Cancer Institute University at Buffalo, New York. Dr. Jain’s clinical interests are urothelial, renal, prostate and testicular cancers with a major focus in urothelial cancers. His research interests are primarily in urothelial and kidney cancers. Dr. Jain is involved in biomarker research as well as developing innovative clinical trials for patients.

Education & Training

Fellowship:

  • Roswell Park Cancer Institute, University of Buffalo - Hematology Oncology

Residency:

  • Johns Hopkins University/Sinai Hospital - Internal Medicine

Medical School:

  • Topiwala National Medical College - MBBS
Participating Trials

CLINICAL TRIAL 19671
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma Metastatic Renal Cell Carcinoma (RCC)
Condition:
Intervention: CB-839/Placebo; Cabozantinib (XL 184); Not Applicable
Open

CLINICAL TRIAL 18788
A Phase 2 Study of Check Point Inhibitor, Durvalumab (MEDI4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
Condition:
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18980
A Phase III, Multicenter, Randomized,Placebo-Controlled, Double-Blind Study of Atezolizumab (AntiPd-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Condition:
Intervention: Atezolizumab (Tecentriq); Placebo
Open

CLINICAL TRIAL 17773
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
Condition:
Intervention: ASG-22CE
Open

CLINICAL TRIAL 19137
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
Condition:
Intervention: Abiraterone acetate; Olaparib (Lynparza); Zytiga (Abiraterone acetate); prednisone
Open

CLINICAL TRIAL 19568
A Randomized Phase 2 Study of Cediranib in Combination with Olaparib versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer.
Condition:
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19435
Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer
Condition:
Intervention: BMS-936558 (Nivolumab); Casodex (Bicalutamide); Lupron (leuprolide acetate); Nivolumab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Jain RK, Gandhi S, George S. Second-line systemic therapy in metastatic renal-cell carcinoma: A review. Urol Oncol. 2017 Nov;35(11):640-646. Pubmedid: 28887097.
  • Miller K, Mehta R, Abraham J, Opneja A, Jain RK. Patterns of Long-term Cancer Survivorship Care in a National Cancer Institute-Designated Comprehensive Cancer Center. Am J Clin Oncol. 2017 Dec;40(6):639-643. Pubmedid: 26359697.
  • Miller KD, Pandey M, Jain R, Mehta R. Cancer Survivorship and Models of Survivorship Care: A Review. Am J Clin Oncol. 2015 Dec;38(6):627-633. Pubmedid: 25635609.
  • Gökmen-Polar Y, Sanders KL, Goswami CP, Cano OD, Zaheer NA, Jain RK, Kesler KA, Nelson RP, Vance GH, Smith D, Li L, Cardoso AA, Badve S, Loehrer PJ, Sledge GW. Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Lab Invest. 2012 Nov;92(11):1564-1573. Pubmedid: 22926645.
  • Vladislav T, Jain RK, Alvarez R, Mehta RJ, Gökmen-Polar Y, Kesler KA, Henley JD, Loehrer PJ, Badve S. Extrathoracic metastases of thymic origin: a review of 35 cases. Mod Pathol. 2012 Mar;25(3):370-377. Pubmedid: 22080058.
  • Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):881-890. Pubmedid: 21503684.
  • Mehta R, Jain RK, Badve S. Personalized medicine: the road ahead. Clin Breast Cancer. 2011 Mar;11(1):20-26. Pubmedid: 21421518.
  • Jain RK, Mehta R, Dimitrov R, Larsson LG, Musto PM, Hodges KB, Ulbright TM, Hattab EM, Agaram N, Idrees MT, Badve S. Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol. 2011 Jul;24(7):917-923. Pubmedid: 21532546.
  • Dundar MM, Badve S, Bilgin G, Raykar V, Jain R, Sertel O, Gurcan MN. Computerized classification of intraductal breast lesions using histopathological images. IEEE Trans Biomed Eng. 2011 Jul;58(7):1977-1984. Pubmedid: 21296703. Pmcid: PMC3328096.
  • Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS. High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology. 2011 Apr;58(5):766-772. Pubmedid: 21401706.
  • Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol. 2010 Feb;23(2):270-275. Pubmedid: 19946260.
  • Jain RK, Mehta RJ, Henley JD, Kesler KA, Loehrer PJ, Badve S. WHO types A and AB thymomas: not always benign. Mod Pathol. 2010 Dec;23(12):1641-1649. Pubmedid: 20834239.
  • Jain RK, Mehta R, Badve S. Conjunctival squamous cell carcinoma due to ocular prostheses: a case report and review of literature. Pathol Oncol Res. 2010 Dec;16(4):609-612. Pubmedid: 20376710.
  • Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol. 2010 Aug;63(8):744-747. Pubmedid: 20702478.
  • Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2010 Aug;123(1):97-108. Pubmedid: 19911270.
  • Jain RK, Aras RY. Depression in geriatric population in urban slums of Mumbai. Indian J Public Health. 2007 Apr;51(2):112-113. Pubmedid: 18240472.